Cannabis Use Disorder

Individuals who required hospital-based care for cannabis use disorder faced nearly three times the risk for premature death, results from a cohort analysis published in JAMA Network Open showed.

The incidence of cannabis use disorder associated with schizophrenia almost tripled among Canadian teenagers and adults after cannabis legalization, according to a study published in JAMA Network Open.

Adults aged 18 to 49 years who used cannabis for medical reasons had higher rates of cannabis use disorder compared with adults who only used cannabis recreationally, according to a research letter published in JAMA Psychiatry.

Genetic predisposition for schizophrenia and frequent use of cannabis both independently corresponded with an increased likelihood of developing psychosis, results of a case-control study showed.

The ACP recently recommended an evidence-based, public health-focused approach to addressing cannabis use.

Individuals with type 2 diabetes who received semaglutide had lower probability for medical care related to tobacco dependence compared with other antidiabetes medications, the results of a study in the Annals of Internal Medicine showed.

Some antipsychotics other than olanzapine lowered the risk for hospitalization due to psychotic relapse among individuals with first-episode psychosis and co-occurring cannabis use disorder, according to a study in Schizophrenia Bulletin.

DENVER — Researchers have recruited women with multiple sclerosis for a study using a home-based telehealth intervention for cannabis use disorder, according to a poster presented at the American Academy of Neurology annual meeting.

Substance use-related CVD deaths increased at an average of 4% per year from 1999 to 2019, with alcohol and opioids the most common contributors, despite an overall reduction in CVD mortality in the U.S. during the same period, data show.

PHILADELPHIA — Two observational studies presented at the American Heart Association Scientific Sessions linked regular marijuana use to elevated risk for HF and elevated risk for major adverse cardiac and cerebrovascular events.